612.11: 616.72 - 002.1 - 022
.., ..
3», , -mail: gp3@admsurgut.ru;
», , -mail:shalabodov@utmn.ru
, (Chlamydia trichomatis, Ureaplasma urealyticum). - IgA, IgG, - , - , . , , .
: , , , ,
ADAPTATION CHANGES OF IMMUNE SYSTEM OF HUMAN ORGANISM AT COMBINED INFLUENCE OF PATHOGENS IN THE CONDITIONS OF MIDDLE PRIOBYE Salyeva L.A., Shalabodov .D.
Municipal budgetary Institution of Public Health Services Surgut Hospital 3,
Surgut, e-mail:gp3@admsurgut.ru;
Tyumen State University, Tyumen, e-mail:shalabodov@utmn.ru
There were held immunology studies of the blood are of people from the Middle Priobye having urogenital infections (Chlamydia trichomatis, Ureaplasma urealyticum). Results of immunology studies revealed the change in the B-cell link of immunity in the direction of increase in the level of IgG, IgA, decrease in activity of T-cell link of immunity, as well as reduction of digest ability of neutrophils against background of high phagocytic activity that lies in the basis of development of secondary immunodeficiency. Persistent immunodeficiency among the people from the Middle Priobye having urogenital infections in hypocomfort climatic conditions declares itself with lingering course chronic infection.
Keywords: blood system, adaptation, hlamydia trichomatis, Ureaplasma urealyticum, Middle Priobye
, , . , [1].
. , , [8].
- , [4].
- , [1].
, , - , - - , [8].
, , [9].
: -
, -
.

247 , 18 69 ; 143 104 , . 8 . 3 : - , 23 17 ; 1 - (, -), 45 30 ; 2 - , 49 38 ; 3 - , 26 19 .
- (-) - (- ) - (-) - - ( ) . . : % , (), (). - (CD4) - (CD8) -. (CD4/CD8). (Ig) , , G ().
t- -
. (), () (), < 0,05; 0,01; 0,001.

. , - [10].
, , [2].
, ^ , ^ ^ - . , [10].
^ I II (. 1). , , , , .
1

. .
n = 40 n = 75 n = 87 n = 45
- % 109/ 16,13 0,66 0,31 0,02 10,40 0,61** 0,23 0,01** 9,23 0,45** 0,83 0,04** 9,85 0,76** 0,45 0,03**
IgA / 1,73 0,28 2,89 0,39** 3,51 0,35*** 2,00 0,29
IgG / 11,02 0,84 15,58 0,45*** 14,78 0,50*** 14,36 0,48**
IgM / 1,75 0,15 1,63 0,26 1,85 0,22 1,43 0,13*
: * - < 0,05; ** - < 0,01; *** - < 0,001 - .
^ , . , ^ [10]. , ^ , III , ^
(. . 1). , ^ ^, ^ ^, ^ [5].
^ . Ig -
, , ^ , , [7]. ^ (. . 1).
. . [6] - . , 4 . . . . [3] ^ 34 % ( < 0,01) . . ^ 62 % ( < 0,01) . . . . , .
- - , (. . 1).
- (. 2), , , - . , -. 4 I, III 8 (. . 2). .
2
-
. .
= 40 = 75 n = 87 = 45
- % 72,27 ± 4,26 65,28 ± 5,52 62,59 4,94* 63,24 6,84
109/ 1,41 ± 0,08 1,22 ± 0,09 1,21 0,05* 1,24 0,09
CD4 % 43,61 ± 1,15 35,00 ± 1,28* 43,87 1,47 41,25 1,78
109/ 0,69 ± 0,02 0,25 ± 0,01** 0,72 0,02 0,21 0,02**
CD8 % 26,53 ± 0,45 18,23 ± 0,48** 17,78 0,33** 17,95 0,54**
109/ 0,45 ± 0,06 0,16 ± 0,04*** 0,28 0,06** 0,18 0,03**
CD4/CD8 - 1,53 ± 0,01 1,56 ± 0,01 2,57 0,02*** 1,17 0,03*
: * - < 0,05; ** - < 0,01; *** - < 0,001 - .
4 8 , [10]. 4/8 II III (. . 2).
-, 4, 8, . [6] . , - 4/8 . 2 ( < 0,001) -
. . - . 14 %, . 2 . - 4/8 51 % . , - , . 45 %, .
, -
. . - [6]. -
, 30 120 - (. 3).
3


. .
n = 40 n = 75 n = 87 n = 45
30 % 82,00 2,38 3,44 0,17 92,00 4,90* 4,50 0,37** 93,56 3,57** 4,70 0,39** 92.61 3,73* 4.61 0,31**
120 % 81,6 4,28 3,45 0,32 96,50 3,00*** 5,30 0,41*** 92,22 5,14** 5,44 0,63*** 98,12 4,35*** 5,37 0,56***
(N > 1) - 1,12 0,07 0,74 0,02* 0,90 0,02* 0,78 0,02*
: * - P < 0,05; ** - P < 0,01; *** - P < 0,001 - -
.
() (. . 3).

, . , . - IgG, IgA . . - . , , .

1. .. / .. , .. , .. . - .: , 2006. - 284 .
2. .. / .. , .. // . . . - 2002. - 2. - . 21-24.
3. .. // . . . -. . - 2003. - 3. - . 54-56.
4. .. / .. , . ,
A.. // - . - 2006. - 1. - . 48-51.
5. , . . - .: », 2003. - 604 .
6. .. - // . . . - 2003. - 3. - . 55-60.
7. . . // . - 2009. - 2. -. 71-76.
8. , .. - // - /
B.. , .. .. - : , 2004. - . 3-13.
9. , .. / .. // . - 2007. - 2. - . 18-23.
10. .. / .. , .. . -.: , 2007. - . 281-346.
:
.., ..., , --», . ;
.., ..., . - », . .
16.08.2011.